Research background · Updated November 1, 2026
BPC-157 Research: Publications, Study Types and Background
Short answer
BPC-157 is listed as synthetic pentadecapeptide (15 amino acids). As of November 1, 2026, PubMed indexes 224 records matching BPC-157, the earliest from 1993; 62 were published in 2021–2025 and 51 are reviews. ClinicalTrials.gov lists 4 registered studies matching the compound.
- PubMed records
- 224
- Earliest record
- 1993
- Published 2021–2025
- 62
- Reviews
- 51
- Animal-only studies
- 103
- Registered studies
- 4
Publications per year, 2006–2025
110 records in 2016–2025 against 53 in 2006–2015; the busiest year was 2021, with 19.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 10 |
| 2010 | 7 |
| 2011 | 6 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 4 |
| 2015 | 6 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 8 |
| 2019 | 5 |
| 2020 | 12 |
| 2021 | 19 |
| 2022 | 13 |
| 2023 | 10 |
| 2024 | 7 |
| 2025 | 16 |
Study types
| All PubMed records | 224 |
|---|---|
| Reviews | 5123% |
| Animal studies (no human subjects indexed) | 10346% |
| Indexed as clinical trials | 00% |
| Registered on ClinicalTrials.gov | 4 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 7 of the most-cited and most recent BPC-157 papers report, in their own authors’ terms. Each line links the paper it came from.
Human studies (systematic review)
This systematic review found three small human studies of BPC-157; all reported symptom improvement in most participants without treatment-related adverse events, but they were judged to be of poor methodological quality and overall certainty of evidence was rated very low.
ReviewPoolton JT 2026Acta orthopaedica BelgicaPMID 42885452
Liver injury models
This narrative review summarizes preclinical reports on BPC 157 across experimental liver injury models, including prevention and reversal of induced portal hypertension, and states that experimental evidence does not establish clinical efficacy and that clinical studies remain necessary.
ReviewSever M 2026Pharmaceuticals (Basel, Switzerland)PMID 42943255
Gastric mucosal protection and nitric oxide
This review summarizes experimental work on how BPC 157 interacts with the nitric oxide system in gastric mucosal protection, blood pressure and cardiovascular models, and notes that how this may translate into clinical performance remains to be determined.
ReviewSikiric P 2014Current pharmaceutical designPMID 23755725
Angiogenesis and VEGFR2 signaling
In rats with hind limb ischemia, BPC 157 was associated with faster blood flow recovery and more vessels; in cultured human endothelial cells it increased VEGFR2 expression and activated VEGFR2-Akt-eNOS signaling, which the authors link to angiogenesis.
RatsHsieh MJ 2017Journal of molecular medicine (Berlin, Germany)PMID 27847966
Wound closure and collagen deposition
In a rat alkali-burn skin model, BPC-157 was reported to accelerate wound closure with more collagen deposition; in cultured human umbilical vein endothelial cells it promoted proliferation, migration and tube formation, which the authors associate with ERK1/2 signaling.
RatsHuang T 2015Drug design, development and therapyPMID 25995620
Tendon fibroblasts and growth hormone receptor
In tendon fibroblasts isolated from rat Achilles tendon, BPC 157 increased growth hormone receptor expression, and added growth hormone then increased cell proliferation; the authors suggest this may contribute to tendon healing.
CellsChang CH 2014Molecules (Basel, Switzerland)PMID 25415472
Tendon outgrowth, cell survival and migration
In rat tendon explants and cultured tendon fibroblasts, BPC 157 accelerated explant outgrowth, increased cell survival under oxidative stress and increased cell migration, while proliferation was not directly affected; the authors link this to activation of the FAK-paxillin pathway.
CellsChang CH 2011Journal of applied physiology (Bethesda, Md. : 1985)PMID 21030672
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 224 of the 224 records. They describe what the literature is about, not what BPC-157 does.
- Anti-Ulcer Agents65 papers
- Wound Healing30 papers
- Stomach Ulcer13 papers
- Nitric Oxide12 papers
- Arginine11 papers
- NG-Nitroarginine Methyl Ester11 papers
- Tendon Injuries8 papers
- Gastric Mucosa8 papers
Key papers
Earliest indexed record
Sikirić P (1993). Journal of physiology, Paris.
PMID 8298609Most-cited paper · 143 citations
Sikirić P (1997). European journal of pharmacology.
PMID 9298922Most-cited #2 · 112 citations
Chang CH (2011). Journal of applied physiology (Bethesda, Md. : 1985).
PMID 21030672Most-cited #3 · 98 citations
Huang T (2015). Drug design, development and therapy.
PMID 25995620
Citation counts from NIH iCite, among the 224 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Synonyms and codes | Body Protection Compound-157, PL 14736, PL-10, PLD-116 |
|---|---|
| Description | Synthetic pentadecapeptide (15 amino acids) |
| Supplied form | Lyophilized powder |
| CAS number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Molecular weight | 1419.5 g/mol |
| Sequence | GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) |
As published by Vanta Labs, with its sources, on the BPC-157 page.
How these numbers were counted
- PubMed search, run November 1, 2026:
"BPC-157"[tiab] OR "BPC 157"[tiab] OR "pentadecapeptide BPC"[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
"BPC-157"re-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use BPC-157 outside a laboratory.
Wholesale supply
BPC-157 for research, documented lot by lot.
5mg, 10mg vials, with a published report printing 99.736% HPLC purity. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
BPC-157 research questions
How much research has been published on BPC-157?
PubMed indexes 224 records matching BPC-157 (searched November 1, 2026), including 51 reviews and 0 records indexed as clinical trials. 62 were published in the five years 2021–2025.
When was BPC-157 first described in the literature?
The earliest PubMed record matching BPC-157 is from 1993 (Sikirić P, Journal of physiology, Paris, PMID 8298609).
What topics does the BPC-157 literature cover?
The subject headings PubMed indexers most often marked as a main topic of BPC-157 papers are Anti-Ulcer Agents, Wound Healing, Stomach Ulcer, Nitric Oxide. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
What is the regulatory status of BPC-157?
Not approved by the U.S. Food and Drug Administration.
Is BPC-157 sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy BPC-157 wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.